Methylcobalamin (Ultra-High Dose B12) for ALS
Also known as: Mecobalamin, Ultra-high dose vitamin B12
Ultra-high dose methylcobalamin (25-50mg) has shown neuroprotective effects in ALS trials, far exceeding standard B12 supplementation doses.
Mechanism of Action
At ultra-high doses, methylcobalamin promotes nerve regeneration through enhanced methylation reactions, supports myelin synthesis, and reduces homocysteine-mediated neurotoxicity. It also serves as a methyl donor for SAM-dependent methyltransferases critical for neuronal gene expression.
General mechanism: Methyl donor supporting nerve regeneration, myelin synthesis, and methylation-dependent neuroprotection at ultra-high doses.
Current Evidence
Japanese Phase III trial (E75, 50mg IM twice weekly) showed significant slowing of ALSFRS-R decline in early-stage patients. Particularly effective when initiated within 12 months of diagnosis. FDA breakthrough therapy review pending.
Clinical Status: Approved in Japan for ALS (2024). Phase III results support efficacy in early-stage patients. FDA review underway.
Safety Profile
Well-tolerated at ultra-high doses in trials. Injection site reactions with IM administration. No significant safety concerns identified.
Key Research Questions
- What is the mechanism behind the dose-response relationship (25mg vs 50mg)?
- Does early initiation (within 6 months of diagnosis) further improve outcomes?
- Can oral ultra-high dose formulations achieve similar CNS levels?